Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AUNG NAING

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1104837590
CMS profile
366226
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$4,309.43

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $3,944.53 10
Food and Beverage $364.90 6

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $4,191.76 15
PFIZER INC. $117.67 1

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AUNG NAING

NPI 1104837590 · CMS profile ID 366226

Allopathic & Osteopathic Physicians / Internal Medicine

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104837590?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104837590?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104837590?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AUNG NAING, NPI 1104837590, CMS profile ID 366226, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1104837590?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $4,309.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $117.6706/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672262367 CMS
Eli Lilly and Company $590.7605/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657686397 CMS
Eli Lilly and Company $79.9705/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657689841 CMS
Eli Lilly and Company $171.1305/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657689843 CMS
Eli Lilly and Company $14.9805/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657693327 CMS
Eli Lilly and Company $110.3804/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657700187 CMS
Eli Lilly and Company $74.9204/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657682831 CMS
Eli Lilly and Company $343.3304/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657682833 CMS
Eli Lilly and Company $116.8204/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657682835 CMS
Eli Lilly and Company $1,131.2004/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657686395 CMS
Eli Lilly and Company $252.4604/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657689839 CMS
Eli Lilly and Company $45.9404/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657693323 CMS
Eli Lilly and Company $21.9904/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657693325 CMS
Eli Lilly and Company $31.4204/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657696735 CMS
Eli Lilly and Company $1,029.9604/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657700183 CMS
Eli Lilly and Company $176.5004/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657700185 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,309.43 16
PY2020 $211.34 1
PY2021 $2,639.00 1
PY2022 $5,205.00 2
PY2023 $3,375.00 2
PY2025 $4,703.88 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,918,481.53 469
PY2024 Recipient $4,531.10 4
PY2024 Principal investigator $4,445,667.71 159
PY2023 Principal investigator $4,761,955.67 97
PY2022 Principal investigator $3,708,621.77 334
PY2021 Principal investigator $5,802,399.26 154
PY2020 Recipient $2,459.66 4
PY2020 Principal investigator $1,927,221.68 148
PY2019 Principal investigator $5,972,979.75 356

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

334 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $207,448.40 12/31/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 940392467
Principal investigator 1 PFIZER INC. $934.91 12/28/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949769547
Principal investigator 1 BioNTech SE $544,440.57 12/22/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT151-01 No dispute reported 06/30/2026 963037536
Principal investigator 1 PFIZER INC. $859.91 12/21/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949769293
Principal investigator 1 Incyte Corporation $1,227.00 12/08/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905246083
Principal investigator 1 PFIZER INC. $934.91 12/07/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949769545
Principal investigator 1 BioNTech SE $4,786.35 12/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037415
Principal investigator 1 PFIZER INC. $2,729.73 11/23/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949781363
Principal investigator 1 Karyopharm Therapeutics Inc. $51,033.17 11/22/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy Agents in Patients with Advanced Malignancies No dispute reported 06/30/2026 956553695
Principal investigator 1 Merck Sharp & Dohme LLC $13,000.00 11/22/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,1b Study of SRF388 in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 940393037
Principal investigator 1 Merck Sharp & Dohme LLC $863,000.00 11/18/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label Phase 1b,2a Study of NT-I7 Hyleukin-7 in Combination with Pembrolizumab in Subjects with Relapsed,Refractory Advanced Solid Tumors No dispute reported 06/30/2026 940388305
Principal investigator 1 Merck Sharp & Dohme LLC $182,000.00 11/15/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A First-in-Human Phase I Study of NL-201 in Patients With Relapsed or Refractory Cancer No dispute reported 06/30/2026 940392437
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,049.90 11/09/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I/II FIH STING Monotherapy/Combination in advanced solid tumors No dispute reported 06/30/2026 933190949
Principal investigator 1 BioNTech SE $7,661.90 11/08/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037407
Principal investigator 1 PFIZER INC. $3,589.64 11/04/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949781399
Principal investigator 1 Merck Sharp & Dohme LLC $56,800.00 11/03/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 940392589
Principal investigator 1 BioNTech SE $289.85 11/02/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037423
Principal investigator 1 PFIZER INC. $859.91 10/22/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949799347
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,260.00 10/20/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE I THROUGH IB AND OR II OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MBG453 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 909387401
Principal investigator 1 BioNTech SE $27,074.20 10/18/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037399
Principal investigator 1 PFIZER INC. $3,053.73 10/07/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949799345
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $50,656.25 10/03/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I IIA DGK FIH Mono Combo in Solid Tumors No dispute reported 06/30/2026 933190771
Principal investigator 1 Incyte Corporation $442.00 09/27/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905246081
Principal investigator 1 Merck Sharp & Dohme LLC $21,300.00 09/22/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,1b Dose Escalation,Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 940392639
Principal investigator 1 PFIZER INC. $3,926.73 09/22/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949799151
Principal investigator 1 Incyte Corporation $66.80 09/09/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218653
Principal investigator 1 Incyte Corporation $64.32 09/09/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218655
Principal investigator 1 Incyte Corporation $37.53 09/09/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218657
Principal investigator 1 Incyte Corporation $30.63 09/09/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218659
Principal investigator 1 Incyte Corporation $116.40 09/09/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218661
Principal investigator 1 Incyte Corporation $50.10 09/09/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218663
Principal investigator 1 Incyte Corporation $30.63 09/09/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218733
Principal investigator 1 Incyte Corporation $64.32 09/09/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218735
Principal investigator 1 Incyte Corporation $37.53 09/09/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218737
Principal investigator 1 Incyte Corporation $50.10 09/09/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218739
Principal investigator 1 Genentech, Inc. $38,024.00 09/07/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
CD25 COMBINATION STUDY WITH ATEZO No dispute reported 06/30/2026 950648835
Principal investigator 1 Merck Sharp & Dohme LLC $189,667.81 09/06/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 940392465
Principal investigator 1 Eli Lilly and Company $1,358.00 08/29/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 STUDY OF PEGILODECAKIN (LY3500518) IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 917821449
Principal investigator 1 BioNTech SE $9,763.10 08/23/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037521
Principal investigator 1 PFIZER INC. $934.91 08/23/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949803735
Principal investigator 1 BioNTech SE $1,245.25 08/17/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037491
Principal investigator 1 Merck Sharp & Dohme LLC $56,800.00 08/15/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1,2 Dose Escalation,Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies No dispute reported 06/30/2026 940392339
Principal investigator 1 BioNTech SE $11,071.25 08/09/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037477
Principal investigator 1 BioNTech SE $33,637.90 08/09/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037529
Principal investigator 1 Genentech, Inc. $56,281.00 08/05/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
CD25 TARGETING BY RO7296682 IN PATIENTS WITH ADVANCED AND OR METASTATIC SOLID TUMOR No dispute reported 06/30/2026 950654565
Principal investigator 1 PFIZER INC. $10,095.43 08/05/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949803695
Principal investigator 1 BioNTech SE $8,805.15 07/27/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037513
Principal investigator 1 BioNTech SE $16,719.50 07/21/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037483
Principal investigator 1 PFIZER INC. $3,589.64 07/21/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949809575
Principal investigator 1 BioNTech SE $1,245.25 07/12/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037469
Principal investigator 1 Merck Sharp & Dohme LLC $97,500.00 07/12/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A multicentre, open-label, non-randomized, phase 1a,1b study of NG 350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours FORTIFY No dispute reported 06/30/2026 940392747
Principal investigator 1 Incyte Corporation $30.92 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218665
Principal investigator 1 Incyte Corporation $35.16 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218667
Principal investigator 1 Incyte Corporation $1.56 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218669
Principal investigator 1 Incyte Corporation $30.63 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218671
Principal investigator 1 Incyte Corporation $12.24 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218673
Principal investigator 1 Incyte Corporation $15.64 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218675
Principal investigator 1 Incyte Corporation $24.08 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218677
Principal investigator 1 Incyte Corporation $48.75 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218679
Principal investigator 1 Incyte Corporation $12.30 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218681
Principal investigator 1 Incyte Corporation $10.20 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218683
Principal investigator 1 Incyte Corporation $2.97 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218685
Principal investigator 1 Incyte Corporation $128.64 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218687
Principal investigator 1 Incyte Corporation $75.06 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218689
Principal investigator 1 Incyte Corporation $6.39 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218691
Principal investigator 1 Incyte Corporation $2.84 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218693
Principal investigator 1 Incyte Corporation $20.26 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218695
Principal investigator 1 Incyte Corporation $1.08 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218697
Principal investigator 1 Incyte Corporation $65.89 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218699
Principal investigator 1 Incyte Corporation $30.63 07/11/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 905218741
Principal investigator 1 PFIZER INC. $14,378.96 07/09/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949809611
Principal investigator 1 BioNTech SE $8,977.70 07/08/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037447
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,941.75 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474967
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,154.94 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474973
Principal investigator 1 Deciphera Pharmaceuticals Inc. $52.17 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474979
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,680.98 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474985
Principal investigator 1 Deciphera Pharmaceuticals Inc. $156.51 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474991
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,818.33 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474997
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,790.86 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475003
Principal investigator 1 Deciphera Pharmaceuticals Inc. $52.17 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475009
Principal investigator 1 Deciphera Pharmaceuticals Inc. $208.68 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475015
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,476.81 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475021
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,052.86 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475025
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,272.62 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475031
Principal investigator 1 Deciphera Pharmaceuticals Inc. $52.17 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475037
Principal investigator 1 Deciphera Pharmaceuticals Inc. $52.17 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475043
Principal investigator 1 Deciphera Pharmaceuticals Inc. $52.17 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475049
Principal investigator 1 Deciphera Pharmaceuticals Inc. $156.51 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475055
Principal investigator 1 Deciphera Pharmaceuticals Inc. $52.17 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475061
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,354.63 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475065
Principal investigator 1 Deciphera Pharmaceuticals Inc. $156.51 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475071
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,545.27 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475077
Principal investigator 1 Deciphera Pharmaceuticals Inc. $374.33 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475083
Principal investigator 1 Deciphera Pharmaceuticals Inc. $104.34 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475089
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,213.99 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475093
Principal investigator 1 Deciphera Pharmaceuticals Inc. $376.79 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475099
Principal investigator 1 Deciphera Pharmaceuticals Inc. $156.51 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475103
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,407.10 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475109
Principal investigator 1 Deciphera Pharmaceuticals Inc. $379.25 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475115
Principal investigator 1 Deciphera Pharmaceuticals Inc. $260.85 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475119
Principal investigator 1 Deciphera Pharmaceuticals Inc. $52.17 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475125
Principal investigator 1 Deciphera Pharmaceuticals Inc. $52.17 07/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953475131
Principal investigator 1 BioNTech SE $19,928.25 06/30/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037783
Principal investigator 1 BioNTech SE $4,125.90 06/22/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037838
Principal investigator 1 Genentech, Inc. $2,619.81 06/21/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
CD25 COMBINATION STUDY WITH ATEZO No dispute reported 06/30/2026 950664793
Principal investigator 1 BioNTech SE $11,308.40 06/16/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037845
Principal investigator 1 BioNTech SE $22,995.05 06/16/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037861
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473797
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473803
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473809
Principal investigator 1 Deciphera Pharmaceuticals Inc. $59.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473813
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,344.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473819
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473825
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473831
Principal investigator 1 Deciphera Pharmaceuticals Inc. $375.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473837
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473843
Principal investigator 1 Deciphera Pharmaceuticals Inc. $618.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473847
Principal investigator 1 Deciphera Pharmaceuticals Inc. $10.78 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473853
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473859
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473865
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473871
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473877
Principal investigator 1 Deciphera Pharmaceuticals Inc. $133.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473883
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473887
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473893
Principal investigator 1 Deciphera Pharmaceuticals Inc. $217.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473899
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473905
Principal investigator 1 Deciphera Pharmaceuticals Inc. $217.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473909
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473915
Principal investigator 1 Deciphera Pharmaceuticals Inc. $103.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473921
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473927
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473933
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473939
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,865.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473945
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473951
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473955
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473961
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473967
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473971
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473977
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473983
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473989
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473993
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953473999
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474005
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474011
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474017
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474023
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474029
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474035
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474041
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474047
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474053
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474059
Principal investigator 1 Deciphera Pharmaceuticals Inc. $50.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474065
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474069
Principal investigator 1 Deciphera Pharmaceuticals Inc. $94.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474075
Principal investigator 1 Deciphera Pharmaceuticals Inc. $50.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474081
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474087
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474093
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474099
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474105
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474111
Principal investigator 1 Deciphera Pharmaceuticals Inc. $618.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474117
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474121
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474127
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474133
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,344.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474139
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474145
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474151
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474157
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474161
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474167
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474173
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474179
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474185
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474191
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474197
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474203
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474209
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474215
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474219
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474225
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474231
Principal investigator 1 Deciphera Pharmaceuticals Inc. $217.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474237
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474242
Principal investigator 1 Deciphera Pharmaceuticals Inc. $10.78 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474247
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474253
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474259
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474265
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474271
Principal investigator 1 Deciphera Pharmaceuticals Inc. $94.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474277
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,344.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474282
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474289
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474295
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474301
Principal investigator 1 Deciphera Pharmaceuticals Inc. $133.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474307
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474311
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474317
Principal investigator 1 Deciphera Pharmaceuticals Inc. $133.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474323
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474329
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474335
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474341
Principal investigator 1 Deciphera Pharmaceuticals Inc. $217.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474347
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474355
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474361
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474367
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474371
Principal investigator 1 Deciphera Pharmaceuticals Inc. $975.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474377
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474383
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474389
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474395
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474401
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474405
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474411
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474417
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474423
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474429
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474435
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474439
Principal investigator 1 Deciphera Pharmaceuticals Inc. $618.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474445
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474451
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474456
Principal investigator 1 Deciphera Pharmaceuticals Inc. $375.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474461
Principal investigator 1 Deciphera Pharmaceuticals Inc. $100.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474467
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474473
Principal investigator 1 Deciphera Pharmaceuticals Inc. $94.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474479
Principal investigator 1 Deciphera Pharmaceuticals Inc. $217.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474485
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474489
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474495
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474501
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474507
Principal investigator 1 Deciphera Pharmaceuticals Inc. $618.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474513
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474519
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474525
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474529
Principal investigator 1 Deciphera Pharmaceuticals Inc. $50.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474535
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474541
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474547
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474553
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474559
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474563
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474569
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474575
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474579
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474585
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474591
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474597
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474603
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474609
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474615
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474621
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474625
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474633
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474637
Principal investigator 1 Deciphera Pharmaceuticals Inc. $100.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474643
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474649
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474655
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474661
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474667
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474673
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474679
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,188.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474685
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474691
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,865.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474697
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474703
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474709
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474715
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474721
Principal investigator 1 Deciphera Pharmaceuticals Inc. $31.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474727
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474731
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,865.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474737
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474743
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474749
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,865.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474755
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474759
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474765
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474771
Principal investigator 1 Deciphera Pharmaceuticals Inc. $209.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474777
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474783
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474789
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474795
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474799
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474805
Principal investigator 1 Deciphera Pharmaceuticals Inc. $100.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474813
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474817
Principal investigator 1 Deciphera Pharmaceuticals Inc. $100.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474823
Principal investigator 1 Deciphera Pharmaceuticals Inc. $169.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474829
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474837
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,125.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474843
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 06/14/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 953474849
Principal investigator 1 PFIZER INC. $2,654.73 06/03/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949810557
Principal investigator 1 BioNTech SE $27,183.00 06/02/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037745
Principal investigator 1 BioNTech SE $15,474.25 06/02/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037753
Principal investigator 1 BioNTech SE $28,443.55 05/25/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037737
Principal investigator 1 PFIZER INC. $9,162.96 05/24/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949754385
Principal investigator 1 BioNTech SE $15,474.25 05/12/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037729
Principal investigator 1 BioNTech SE $7,303.20 05/12/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037807
Principal investigator 1 PFIZER INC. $7,322.76 05/06/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949754391
Principal investigator 1 BioNTech SE $7,082.20 05/05/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037767
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,461.00 04/22/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I II FIH STING Monotherapy Combination No dispute reported 06/30/2026 933190681
Principal investigator 1 PFIZER INC. $21,981.55 04/22/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949815895
Principal investigator 1 BioNTech SE $3,903.20 04/21/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037815
Principal investigator 1 BioNTech SE $14,623.40 04/21/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037831
Principal investigator 1 SANOFI US SERVICES INC. $2,857.70 04/19/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
New TED/TCD --- Phase 1 Oncology No dispute reported 06/30/2026 935629051
Principal investigator 1 SANOFI US SERVICES INC. $3,766.00 04/19/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
New TED/TCD --- Phase 1 Oncology No dispute reported 06/30/2026 935629062
Principal investigator 1 BioNTech SE $3,124.60 04/13/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037823
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,570.60 04/13/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) No dispute reported 06/30/2026 933187671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40,930.58 04/13/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH - 1 (PD 1), AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 938612505
Principal investigator 1 BioNTech SE $11,945.05 04/11/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037775
Principal investigator 1 PFIZER INC. $7,072.65 04/08/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949815893
Principal investigator 1 BioNTech SE $2,500.00 03/23/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037683
Principal investigator 1 BioNTech SE $6,875.00 03/23/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037691
Principal investigator 1 BioNTech SE $22,755.35 03/23/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037699
Principal investigator 1 BioNTech SE $47,125.00 03/23/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037705
Principal investigator 1 PFIZER INC. $148,596.58 03/23/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949820029
Principal investigator 1 Novartis Pharmaceuticals Corporation $60,729.47 03/22/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE I AND OR II OPEN LABEL MULTI CENTER STUDY OF THE SAFETY AND EFFICACY OF BLZ945 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULTS PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 909387499
Principal investigator 1 BioNTech SE $6,373.83 03/17/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT151-01 No dispute reported 06/30/2026 963037599
Principal investigator 1 BioNTech SE $28,441.85 03/17/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037659
Principal investigator 1 BioNTech SE $50,512.95 03/10/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037621
Principal investigator 1 PFIZER INC. $3,840.76 03/03/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949820059
Principal investigator 1 BioNTech SE $15,474.25 02/17/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037651
Principal investigator 1 SANOFI US SERVICES INC. $37,426.35 02/15/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
New TED/TCD --- Phase 1 Oncology No dispute reported 06/30/2026 935628695
Principal investigator 1 BioNTech SE $9,242.05 02/10/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037713
Principal investigator 1 PFIZER INC. $2,045.94 02/05/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949820213
Principal investigator 1 BioNTech SE $49,536.70 02/03/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT151-01 No dispute reported 06/30/2026 963037591
Principal investigator 1 BioNTech SE $2,612.05 02/03/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037643
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $179.00 01/31/2022 Non-covered Recipient Entity
University Of Texas Md Anderson Cancer Center-Investigational Cancer Therapeutics
Phase I/IIA FIH CCR8 Mono/Combo - A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors No dispute reported 06/30/2026 933191063
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,019.00 01/27/2022 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I II FIH STING Monotherapy Combination in advanced solid tumors No dispute reported 06/30/2026 933190683
Principal investigator 1 BioNTech SE $2,834.75 01/25/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037667
Principal investigator 1 BioNTech SE $6,484.65 01/20/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037675
Principal investigator 1 BioNTech SE $21,771.05 01/12/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037629
Principal investigator 1 PFIZER INC. $2,405.80 01/08/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949823407
Principal investigator 1 BioNTech SE $4,125.90 01/07/2022 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
BNT152-01C No dispute reported 06/30/2026 963037635